Biomm S.A. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was BRL 118.19 million compared to BRL 104.95 million a year ago. Net loss was BRL 81.14 million compared to BRL 92.56 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.96 BRL | -2.44% | -11.33% | +176.12% |
Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
Apr. 17 | Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A | CI |
1st Jan change | Capi. | |
---|---|---|
+176.12% | 275M | |
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |
- Stock Market
- Equities
- BIOM3 Stock
- News Biomm S.A.
- Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023